Topas Therapeutics, which is exploiting University of Hamburg research, has pocketed $26m in its series B round.

Topas Therapeutics, a Germany-based developer of treatments for autoimmune diseases based on research at University of Hamburg, closed a €22m ($26m) series B round yesterday co-led by Vesalius BioCapital III and BioMedPartners. All existing shareholders – EMBL Ventures, the investment arm of European Molecular Biology Laboratory, commercialisation firm Epidarex Capital, drug discovery company Evotec, pharmaceutical…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.